Founded by 4 scientists from the University of Oxford, HKUST, Utrecht University, and Universität Bonn, we are developing technologies to automate the moving parts of the healthcare sector in a frictionless manner. Supported by Cyberport and HKUST, we are humbled to be supporting multiple institutions in their fight against COVID-19 and Cancer. Our line of Healthcare technologies include patient triaging, treatment analysis, cancer early detection, patient outcome prediction, hospital resource forecasting, etc.
Location: United Kingdom
Employees: 11-50
Total raised: $5M
Founded date: 2021
Investors 1
| Date | Name | Website |
| 13.04.2024 | Berkeley S... | skydeck.be... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.01.2026 | Seed | $5M | Berkeley S... |
Mentions in press and media 4
| Date | Title | Description |
| 14.01.2026 | Allos AI Secures $5M to Revolutionize Drug Formulation with Causal AI | Allos AI secures $5M seed funding. The UK firm uses 'glass-box' Causal AI to revolutionize drug reformulation. It targets existing complex medicines, enhancing patient tolerability and adherence. Pharma often neglects post-approval drug opt... |
| 12.01.2026 | Allos Raises $5M in Seed Funding | Allos, an Oxford, UK-based company using causal AI for clinical outcomes, raised $5M in Seed funding. the round was led by Oxford Science Enterprises (OSE) with participation from Habico Invest, the family office of Danish pharmaceutical gr... |
| 12.01.2026 | Allos AI Raises $5M to Reformulate Complex Drugs with Glass-Box Causal AI | What You Should Know – Allos AI has emerged from stealth with $5 million in seed financing led by Oxford Science Enterprises (OSE) to commercialize the industry’s first “glass-box” Causal AI platform. – Unlike traditional AI that focuses on... |
| - | Allos | “Allos replaces trial-and-error with causal AI to bring physical rigor to pharmaceutical manufacturing, reducing experiments and making decisions evidence-based and defensible.” |